Work

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-148700

Authors: Guy Young, Mark T Reding, Robert F. Sidonio, Doris V. Quon, Janice M. Staber, Cindy A. Leissinger, Jessica Charlet, Moncef Boukerrou

Institutions: University of Southern California, Children's Hospital Los Angeles, University of Minnesota Medical Center, Emory University, Orthopaedic Institute for Children, University of Iowa Stead Family Children’s Hospital, Tulane University, Bayer (United States)

Language: English

Topic: Hemophilia Treatment and Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3211624280

Cites:

Cited by: 1

Related to: 10